IN2014DN01629A - - Google Patents
Info
- Publication number
- IN2014DN01629A IN2014DN01629A IN1629DEN2014A IN2014DN01629A IN 2014DN01629 A IN2014DN01629 A IN 2014DN01629A IN 1629DEN2014 A IN1629DEN2014 A IN 1629DEN2014A IN 2014DN01629 A IN2014DN01629 A IN 2014DN01629A
- Authority
- IN
- India
- Prior art keywords
- tehinhibition
- traeting
- medicaments
- substituents
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The invention relates to compound of the formula I (I) or a salt thereof wherein the substituents are as defined in the specification; to its preparation and to medicaments comprising it for traeting diseases connected to tehinhibition of H3 receptor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011080529 | 2011-10-08 | ||
CN2012081326 | 2012-09-13 | ||
PCT/IB2012/055424 WO2013050987A1 (en) | 2011-10-08 | 2012-10-08 | Carbamate/ urea derivatives containing piperidin and piperazin rings as h3 receptor inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN01629A true IN2014DN01629A (en) | 2015-05-15 |
Family
ID=47278913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1629DEN2014 IN2014DN01629A (en) | 2011-10-08 | 2012-10-08 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9216182B2 (en) |
EP (1) | EP2763978B1 (en) |
JP (1) | JP6046149B2 (en) |
KR (1) | KR20140072076A (en) |
CN (1) | CN103917534B (en) |
AR (1) | AR088256A1 (en) |
AU (1) | AU2012320038A1 (en) |
BR (1) | BR112014007578A2 (en) |
CA (1) | CA2851405A1 (en) |
EA (1) | EA201490754A1 (en) |
ES (1) | ES2624421T3 (en) |
IN (1) | IN2014DN01629A (en) |
MX (1) | MX2014004254A (en) |
TW (1) | TW201321353A (en) |
WO (1) | WO2013050987A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9034874B2 (en) * | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
CA2934700A1 (en) | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Glutaminase inhibitors |
EP3391886A1 (en) | 2017-04-19 | 2018-10-24 | Novartis AG | The use of a h3r inverse agonist for the treatment of shift work disorder |
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
CN109666020A (en) * | 2018-12-20 | 2019-04-23 | 苏州麦迪耐斯医药科技有限公司 | A kind of new compound and its preparation method and application |
CN111057045A (en) * | 2019-12-18 | 2020-04-24 | 安徽红杉生物医药科技有限公司 | HCV NS3/4A protease inhibitor intermediate, and synthesis method and application thereof |
WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513135A (en) * | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
FR2567518B1 (en) * | 1984-07-11 | 1987-11-13 | Sanofi Sa | NOVEL NITROGEN HETEROCYCLIC CORE COMPOUNDS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME |
US5124457A (en) | 1986-05-21 | 1992-06-23 | Abbott Laboratories | Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies |
TW301607B (en) * | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
JPH06316522A (en) * | 1993-03-09 | 1994-11-15 | Takeda Chem Ind Ltd | Cell adhesion inhibiting agent |
CN1298715C (en) | 2001-03-13 | 2007-02-07 | 先灵公司 | Non-imidazole compounds as histamine H3 antagonists |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
DK1615909T3 (en) | 2003-04-23 | 2008-11-17 | Glaxo Group Ltd | Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders |
SE0401971D0 (en) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
US7851474B2 (en) * | 2005-08-02 | 2010-12-14 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
JP2009514846A (en) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | Tetrahydronaphthyridine derivatives |
WO2007063934A1 (en) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | Alicyclic heterocyclic compound |
ES2601007T3 (en) | 2010-01-22 | 2017-02-13 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound that has a PGDS inhibitory effect |
US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
-
2012
- 2012-10-05 AR ARP120103727A patent/AR088256A1/en not_active Application Discontinuation
- 2012-10-05 TW TW101137030A patent/TW201321353A/en unknown
- 2012-10-08 AU AU2012320038A patent/AU2012320038A1/en not_active Abandoned
- 2012-10-08 ES ES12795066.5T patent/ES2624421T3/en active Active
- 2012-10-08 JP JP2014534037A patent/JP6046149B2/en active Active
- 2012-10-08 WO PCT/IB2012/055424 patent/WO2013050987A1/en active Application Filing
- 2012-10-08 BR BR112014007578A patent/BR112014007578A2/en not_active Application Discontinuation
- 2012-10-08 EP EP12795066.5A patent/EP2763978B1/en active Active
- 2012-10-08 IN IN1629DEN2014 patent/IN2014DN01629A/en unknown
- 2012-10-08 EA EA201490754A patent/EA201490754A1/en unknown
- 2012-10-08 MX MX2014004254A patent/MX2014004254A/en not_active Application Discontinuation
- 2012-10-08 KR KR1020147008869A patent/KR20140072076A/en not_active Application Discontinuation
- 2012-10-08 CA CA2851405A patent/CA2851405A1/en not_active Abandoned
- 2012-10-08 CN CN201280049386.4A patent/CN103917534B/en active Active
- 2012-10-08 US US14/350,159 patent/US9216182B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20140072076A (en) | 2014-06-12 |
EA201490754A1 (en) | 2014-07-30 |
AU2012320038A1 (en) | 2014-04-24 |
JP6046149B2 (en) | 2016-12-14 |
MX2014004254A (en) | 2014-10-17 |
WO2013050987A9 (en) | 2013-07-25 |
AR088256A1 (en) | 2014-05-21 |
WO2013050987A1 (en) | 2013-04-11 |
US9216182B2 (en) | 2015-12-22 |
US20140235609A1 (en) | 2014-08-21 |
CN103917534A (en) | 2014-07-09 |
CA2851405A1 (en) | 2013-04-11 |
TW201321353A (en) | 2013-06-01 |
ES2624421T3 (en) | 2017-07-14 |
BR112014007578A2 (en) | 2017-04-11 |
EP2763978A1 (en) | 2014-08-13 |
CN103917534B (en) | 2016-11-16 |
JP2014530807A (en) | 2014-11-20 |
EP2763978B1 (en) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN01629A (en) | ||
NZ608116A (en) | Triazine-oxadiazoles | |
PH12014502733A1 (en) | Neprilysin inhibitors | |
MY163394A (en) | Substituted aminobutyric derivates as neprilysin inhibitors | |
IN2015DN03998A (en) | ||
MY176126A (en) | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | |
UA110354C2 (en) | Anti-viral compounds | |
MY165087A (en) | Neprilysin inhibitors | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
ZA201206254B (en) | Novel salts for the manufacture of pharmaceutical compositions | |
IN2014CN04530A (en) | ||
IN2015DN01119A (en) | ||
IN2014DN10449A (en) | ||
WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
MX2014010433A (en) | Novel crystalline form of sitagliptin sulfate. | |
MY160902A (en) | Process for the preparation of the L-arginine salt of perindopril | |
PH12018501709A1 (en) | Naphthridinedione derivatives | |
PH12015500373B1 (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease | |
MX2014009084A (en) | Pyrimidooxazocine derivatives as mtor - inhibitors. | |
IN2014DN07498A (en) | ||
TN2013000089A1 (en) | Triazine-oxadiazoles | |
TN2013000035A1 (en) | Highly crystalline valsartan |